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HIGHLIGHTS 
 Increased immune function in First Episode Psychosis patients compared to 
prodromal subjects. 
 Serum cortisol secretion and fluctuation differed between the groups only at 
a trend level. 
 Suppression of HPA axis capacity did not differ significantly between groups. 
 No significant associations among cytokines, cortisol and psychopathology.  
 
ABSTRACT 
The aim of the study was to gauge both the immune and neuroendocrine function in 
Ultra High Risk for psychosis (UHR) subjects and compare them with a cohort 
presenting with First Episode Psychosis (FEP).     
We recruited two groups, the first group consisted of 12 UHR males and the second  
of 25 males with FEP.  We measured serum cortisol levels at 08:00, 12:00, 18:00 with 
their Area Under Curve with respect to the ground (AUCg) and the increase (AUCi) 
and we measured serum cytokines levels, Interleukin-1a, IL-1a, IL-2, IL-4,IL-5,IL-6,IL-
8, IL-10,IL-12, IL-17a, Tumor Necrosis Factor-a (TNF-a), Interferon-γ (IFN-γ). 
Dexamethasone Suppression Test (DST) was also performed .  
The results suggest higher levels of both pro-inflammatory (TNF-a, IL-2, IL-12, IFN-γ) 
and anti-inflammatory (IL-10) cytokines in the FEP group compared with the UHR 
counterparts. Regarding the HPA axis function, the prodromal subjects showed a 
trend for higher AUCg and AUCi change/decrease cortisol levels. On the contrary, the 
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DST results did not differ between the groups. No significant associations were 
demonstrated within each group among cytokines, cortisol and psychopathology. 
The findings favor a hypothesis of a relatively increased mobilization of both the pro- 
and anti-inflammatory cytokine networks, in FEP compared with that of UHR 
subjects.  
Keywords: Cytokines, Cortisol, First Episode Psychosis, HPA axis, Immunity, 
Inflammation, Ultra High Risk. 
 
1. Introduction 
The neural diathesis-stress model (Walker and Diforio, 1997) of psychosis has been a 
widely used model to explain the neurobiological basis of the vulnerability the 
psychotic patients demonstrate to different stressors. Thus, research has focused on 
the Hypothalamus-Pituitary-Adrenal (HPA) axis function which is known to mediate 
the organism’s response to stressful stimuli so as homeostasis and psychosomatic 
equilibrium to be maintained (Chrousos, 2000). 
Recent research to elucidate the causes of stress vulnerability in psychosis, has 
involved the study of the HPA axis function in cohorts presented with First Episode 
Psychosis (FEP), as this group eliminates confounders such as medication and 
chronicity. The evidence from this approach favors an up regulation of basal cortisol 
secretion in individuals with FEP vs Healthy Controls (HC). In contrast, the reactive 
capacity of the HPA axis function and its relation to specific psychopathology remain 
vague (Karanikas et al., 2014). In addition, there is similar evidence for up regulation 
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of cortisol secretion even prior to the emergence of a full blown psychotic episode, 
that being at prodrome (Karanikas and Garyfallos, 2015). Indeed, the psychotic 
prodromal period is characterized by the emergence of a constellation of sub 
threshold psychotic-like symptoms and progressive functional decline that can 
precede the onset of an Axis I psychotic disorder. Preliminary evidence suggests a 
pattern where cortisol levels in At Genetic Risk of Psychosis cohorts tended to be 
numerically intermediate between the patients group (established psychosis) and 
the HC (Spelman et al.,2007; Yildirim et al., 2011) . Similarly to the evidence coming 
from FEP studies, cortisol’s fluctuation and reactivity to different stressors in Ultra 
High Risk of psychosis (UHR) subjects compared with HC, remain vague due to the 
minimal literature and divergent results (Karanikas and Garyfallos, 2015).  
A similar obscurity characterizes the findings in relation to the immune abnormalities 
in psychosis. The first attempts to review the studies evaluating circulating cytokines 
produced conflicting results (Drzyzga et al., 2006; Potvin et al., 2008; Miller et al., 
2011). Heterogeneity appeared to be a common denominator in these studies. This 
heterogeneity related to differences in diagnoses, setting, medication, phase of 
illness, comorbidity. The hypotheses referring to the immune aetiopathological 
backround in psychosis involve i. the macrophage-T Lymphocyte theory (Smith and 
Maes, 1995), ii. the T helper type 2 shift (Müller and Schwarz, 2010), iii. the microglia 
activation (Monji et al., 2009), iv. the tryptophane metabolism-kynourenine pathway 
and astrocyte activation (Müller et al., 2011), v. the synchronous activation of both 
pro- and anti- inflammatory arms of immunity (Drexhage et al., 2011).  
5 
 
This present study constitutes a preliminary attempt to capture the immune and 
HPA axis function profile in 2 cohorts, whose clinical presentation lied in close 
proximity to the emergence of psychosis. The first group incorporated FEP patients 
and the other UHR subjects. The HPA axis function was investigated in a way to 
capture evidence not only for the total secretion of cortisol but also its fluctuation 
throughout time. Plus HPA axis’ reactivity/suppressor capacity was gauged with the 
implementation of the Dexamethasone Suppression Test (DST). In addition, a group 
of cytokines alleged to serve different immune functions (innate vs adaptive, pro- vs-
anti- inflammatory arms) were evaluated. As mentioned before, the data regarding 
the immune and neuroendocrine profile in the FEP and the prodromal state are 
minimal and to an extent contradictory.  
To our knowledge this is the first study involving a direct comparison of cytokines 
profile and HPA axis function between the prodrome and the FEP. Given the 
evidence that inflammation may underlie the aetiopathogenetic substrate of 
psychosis, we  tested the hypothesis that the FEP group (where full blown psychosis 
becomes clinically evident) would demonstrate increased immune mobilization as 
well as increased cortisol secretion and/or fluctuation and more blunted cortisol 
suppression on the DST compared with the UHR group (where the psychotic 
symptomatology is clinically demonstrated in a more attenuated fashion) . 
2. Methods   
2.1 Subjects 
     The study was conducted, from May 2012 up until May 2014, within the settings 
of two psychiatric clinics; the Psychiatric Department of the 424 General Military 
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Hospital of Thessaloniki and the 2nd Psychiatric Department of Aristotle University 
of Thessaloniki, located at the Psychiatric Hospital of Thessaloniki, Greece.   
    The recruitment of the FEP group involved 25 male patients with their first 
presentation of psychotic episode without affective features. We recruited 
participants having received a diagnosis of Brief Psychotic disorder or 
Schizophreniform disorder or Schizophrenia or Psychotic disorder Not Otherwise 
Specified according to the DSM IV-TR. Drug induced psychosis was excluded, based 
on the history, clinical presentation and urine drug test. Both the FEP group and the  
UHR group (N=12 males) consisted of military personnel who were referred to the 
Psychiatric Department of the 424 General Military Hospital of Thessaloniki, Greece 
for further evaluation of their change/deterioration in their behavior and/or function 
in their military duties. 
 2.2 Clinical assessment    
2.2.1 Clinical Diagnoses  
The referred subjects (military male personnel) were clinically evaluated by two 
psychiatrists (EK, GG) not being the principal treating doctors of the patients. 
Diagnoses of FEP patients were confirmed with the application of the Structured 
Clinical Interview (SCID)(First et al., 2002) for DSM-IV-TR. Regarding the UHR group, 
their recruitment was based on the PACE criteria (Yung et al., 1998) using the 
Comprehensive Assessment of At Risk Mental States (CAARMS) (Yung et al., 2005). 
According to the pre mentioned classification,  UHR individuals must meet at least 
one of the following constellations of criteria: (a) Attenuated Psychotic Symptoms 
(APS); denoting the  experience of sub threshold positive psychotic symptoms during 
7 
 
the past year; (b) Brief Limited Intermittent Psychotic Symptoms( BLIPS); the 
experience of episodes of frank psychotic symptoms that have not lasted longer than 
a week and have been self-remitting; or (c) Trait and State Risk Factor; having a first 
degree relative with a psychotic disorder or the identified subject has been 
diagnosed with Schizotypal Personality Disorder (SPD) plus a significant decrease in 
functioning during the previous year. No subjects were diagnosed with any other 
comorbid psychiatric state. 
2.2.2 Psychopathology severity 
      The symptom severity in both the FEP and UHR groups was assessed with the 
Greek version (Lykouras et al., 1994) of the Structured Clinical Interview for the 
PANSS (Kay et al., 1987) and was performed by two psychiatrists (EK, GG) on the 
same day or within the next two days of blood sampling. The results were calculated 
as Positive Factor (PANSS PF), Negative Factor (PANSS NF), General Psychopathology 
(PANSS GP) and Total score (PANSS TOTAL).  
 
2.3 Other Inclusion-exclusion criteria    
 We included FEP subjects who were medication naïve or minimally treated; the later 
meaning that, depending on their clinical presentation they should not have been for 
more than 3 days on any type of psychotropic medication (antipsychotic, mood 
stabilizer, antidepressant, benzodiazepines) up until all blood sampling had been 
completed. In this way the least possible exposure to the effects of medication was 
ensured. The UHR participants needed to be drug naïve to be included in the study. 
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   Our study groups consisted of participants between the age group of 18-40, with 
BMI<30. Also the design of the study required the participants to be physically 
healthy with no signs of active inflammation for at least 15 days prior to the study -
based on the medical history, physical clinical examination and laboratory 
investigations.  
We excluded subjects with intellectual disability, shift workers and illicit drug use 
based on history and urine drug tests both at their admission in hospital and prior to 
that at random sampling according to the practices of the Greek Armed Forces. 
Participants with any chronic medical state (including but not restricted to impaired 
thyroid function, polydipsia, asthma, diabetes, chronic fatigue, autoimmune 
disorders) or medication that could impair the immunological, endocrinological or 
neurological status were excluded.  
     All participants gave their informed consent after a thorough explanation was 
provided regarding the process. The local ethical scientific committees of the two 
involved hospitals, plus the scientific committee of the Headquarters of the Greek 
Armed Forces gave their consent for the study. The study was performed in 
accordance with the last edition of the Declaration of Helsinki.   
2.4 Blood collection and analyses 
The blood samples were collected within the first 3 days of admission for both the 
FEP and the UHR subjects. The day 1 of blood sampling, samples were collected at 3 
separate points in time; 08:00 morning, 12:00 midday and 18:00 noon. At 23:00 of 
the first day, 1 mg of Dexamethasone (Dex), was given. At day 2, post/Dex, at 08:00 
another blood sample was collected. All subjects were instructed to keep fasting 
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overnight up until the morning samples were given. The participants were also 
instructed to abstain from caffeine, alcohol, cigarette and physical exercise at least 
30 min prior to any blood sampling. Every blood sample was centrifuged at 3000xg 
for 5 min and the serum was stored at deep freezer -80 C, until assayed. 
2.4.1 Cortisol measurement 
Cortisol was measured from the 3 samples at day 1 and the post-Dex sample at day 
2. Serum cortisol levels were analyzed with radioimmunoassay using the DIA source 
CORTISOL-RIA-CT Kit manufactured by DIA source ImmunoAssays S.A.Rue du 
Bosquet, 2, B-1348 Louvain-la-Neuve, Belgium according to the manufacturer 
instructions. All cortisol samples were thawed at the same day and the assays were 
carried out in one and the same run. 
2.4.2 Cytokines measurement 
 The cytokines were measured from the serum samples from day 1 at 08:00 so as not 
be affected by Dex. The cytokine evaluation involved the principles of Fluorescent 
Bead Immunoassay and the FlowCytomix. The kits used were the Flowcytomix  
Human Th1/Th2 11plex Kit [Interferon-γ (IFN-γ), Interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-
6, IL-8, IL-10, IL-12 p70, Tumor Necrosis Factor (TNF)-a, TNF-b] BMS810FF and the 
Flowcytomix BMS82017FF human IL-17A simplex kit of the Bender Med Systems 
GmbH Campus Vienna Biocenter 2, A-1030 Vienna, Austria, Europe according to the 
manufacturer instructions. All cytokine samples were thawed at the same day and 
the assays were carried out in one and the same run. 
2.5 Statistical analysis  
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 All subsequent statistical analyses were carried out using SPSS version 20. Due to 
marked deviations from normality all cytokine values were logarithmically 
transformed. Additionally, non-parametric statistics were employed to alleviate 
issues with any residual skewness. Intra-group correlations were assessed with the 
Spearman r statistic. Group differences on cytokine values were assessed by way of 
the Mann-Whitney test (alpha set at .05 in all cases).   
Cortisol measurement were undertaken three times during the day at 08:00, 12:00 
and 18:00, prior to administration of Dex. We measured the respective values across 
the timeframe and assessed their total area under the curve to determine group 
differences. We employed two formulas in the computations, the ‘area under the 
curve with respect to increase’ (AUCi) and ‘area under the curve with respect to 
ground’ (AUCg) as described in Pruessner et al., (2003). With endocrinological data, it 
can be assumed that the use of the AUCg will result in a measure that is more related 
to ‘total hormonal output’, whereas the use of AUCi is more related to the sensitivity 
of the system, pronouncing changes over time. We have also computed the absolute 
difference between cortisol values pre- and post- administering dexamethasone 
(pre-post/Dex cort). We also compared the rate of cortisol suppressors of each 
group depending on whether they showed post/Dex cort values below the cutoff 
5μg/dl (Meikle et al., 1975). 
3. Results  
3.1 Descriptive statistics  
 Group demographics, clinical data, cortisol and cytokine measurements are 
presented in Table 1. Four FEP group patients were diagnosed with Brief Psychotic 
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disorder, 16 with Schizophreniform disorder, 1 with Schizophrenia and 4 with 
Psychotic disorder Not Otherwise Specified. The mean(±SD) Duration of their 
Untreated Psychosis (DUP) was estimated to be 14.8(±6.3) weeks.  Similarly, 8 UHR 
individuals presented with APS, 2 with BLIPS and 2 were diagnosed with SPD plus 
functional deterioration during the past year. Fourteen FEP patients (14/25; 56%) 
and 7 UHR (7/12; 58.3%) subjects were currently smokers (χ2=0.018, p=0.89). The 
groups did not differ significantly in age, education, smoking and BMI (all p>0.05). 
Eight (32%) out of 25 FEP patients were under treatment (risperidone, olanzapine, 
quetiapine, haloperidol) for a mean of 1.75±0.8 days. The mean daily 
Chlorpromazine equivalent dose was 555.3±388 mg. All the UHR subjects were drug 
naïve. Age, education, smoking and BMI did not correlate significantly with the 
cortisol levels nor did they with the cytokine levels (all p>0.05). Neither was the 
medication within the FEP group correlated significantly with either the cortisol or 
cytokine levels (all p>0.2). Based on the insignificant correlations of cortisol and 
cytokines levels with the pre-mentioned confounders, no further control analyses 
were carried out. Clinical assessment of the psychopathology, measured with PANSS, 
and the scores (PF, NF, GP and TOTAL)  showed statistically significant differences 
between the two groups, with the FEP group, as it was expected, exhibiting higher 
levels of psychopathology in all measured dimensions, all p≤0.001(See Table 1).  
3.2 Group comparisons for cytokine levels 
    Comparisons of cytokines, with the Mann-Whitney test, revealed statistically 
significant differences between study groups (Table 1). In particular, TNF-a(U=67.5, 
Z=2.846, p=0.004), IL-2(U=79, Z=2.306, p=0.021), IFN-γ(U=68, Z=2.664, p=0.008), IL-
12p70(U=79, Z=2.307, p=0.021) and IL-10(U=76, Z=2.407, p=0.016) levels in the FEP 
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group were significantly higher compared with the UHR counterparts( Figure 1). IL-6 
and IL-17A levels were below the detection limit in more than 50% of the subjects in 
each cohort, therefore they were omitted from further analysis. 
3.3 Group comparisons for cortisol levels 
The mean and SD values for AUCg, AUCi, pre-post/Dex cort for both FEP and UHR 
groups are shown in Table 1.   
The prodromal group exhibited higher AUCg cortisol values, at a trend level 
(U=97.5, Z=1.70, p=0.088), in relation to the FEP group. Both groups showed 
negative mean AUCi values indicating that cortisol was decreasing during the day 
and the decrease was higher, at a trend level (U=93, Z=1.849, p=0.064), in the UHR 
compared with the FEP group. In regards to the pre-post/Dex cort, the 2 groups 
did not show significant difference (U=109, Z=1.33, p=0.183). Two subjects from 
the FEP group (2/25; 8%) suppressed post/Dex cort below the cutoff (5 μg/dl) as 
opposed to none from the UHR group (χ2=1.015, p=0.313). Interestingly, when the 
cutoff limit was reduced to 2 μg/dl, based on new literature suggesting that most 
normal individuals suppress their 8 am cortisol value to less than 2 μg/dL (Blethen 
and Chasalow, 1989), then 4/25 (16%) FEP patients were deemed non-suppressors 
whereas there was no change in the UHR group (0%); again the suppressors’ rate 
did not differ significantly between the compared groups (χ2=2.15, p=0.142).  
3.4 Correlations within each group 
In the FEP group, TNF-a was positively associated with IL-10(r=+0.786, p<0.001), 
whereas in the UHR this association was significant but negative(r=-0.589, p=0.044).  
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No significant correlations (all p>0.05) were demonstrated among the cytokines, 
cortisol and psychopathology within each of the 2 study groups.  
4. Discussion 
The results of the current study is a first report of a direct comparison of both the 
immune and neuroendocrine profile between FEP and UHR subjects. Thus, this study 
constitutes a first approach to comprehend the immune-endocrine alterations 
during the very initial stage of psychosis, even before the emergence of the full 
syndrome. The results suggest significantly higher levels of TNF-a, IL-2, IL-12, IFN-γ 
and IL-10 in the FEP group, compared with the UHR counterparts. Whereas the 
results regarding the HPA axis function, show higher mean AUCg and similarly higher 
AUCi cortisol change/decrease at trend level in the prodromal group, yet failing to 
reach statistical significance. Additionally, the cortisol suppression rate on DST did 
not differ between the groups. TNF-a was associated with IL-10, within each group, 
but with an inversive mode (positively within the FEP vs negatively in the UHR). No 
significant associations were demonstrated among the cytokines, cortisol and 
psychopathology, within each group. 
4.1 Cytokines 
According to the literature, an increase of TNF-a was evident in a number of studies 
(Fernandez-Egea et al.,2009; Kaminska et al., 2001; Kim et al., 2009) on psychosis, 
with varied designs, diagnoses, medication status, phase of illness. Two recent 
reviews (Miller et al., 2011; Kirkpatrick and Miller, 2013) suggested that TNF-a as 
well as IFN-γ and IL-12  may be classified as trait biomarkers in schizophrenia, as it 
seems that they remain increased even after medication. A recent study (Mondelli et 
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al., 2015) showed increased TNF-a and IFN-γ in FEP subjects compared with HC, with 
the later cytokine playing a predictive role in the outcome of response to treatment.   
Our finding of a simultaneous increase of TNF-a along with cytokines of the cell 
mediated immunity and specifically from the T helper type 1 immune response such 
as IFN-γ and IL-2, could imply an increase of magnitude of the pro-inflammatory 
process. This increase seems to coincide with the emergence of a full blown 
psychotic episode, being evident in our FEP group, as opposed to the UHR 
counterparts. The differences of the cytokines levels between the groups are unlikely 
to be attributed to demographic confounding variables such as gender, age, BMI, 
education, smoking since (a) the groups were matched for these parameters and (b) 
the correlations of the demographic parameters with the cytokines levels were 
insignificant. Neither could the medication factor account for the differences since 
its correlation with the deviated cytokines was insignificant and the exposure was 
minimal (mean of 1.75±0.8 days). Plus, to our knowledge there is no study of the 
medication effect on the cytokines levels in vivo for such a minimal exposure and 
even a recent review (Baumeister et al., 2016) noted many inconsistencies between 
the in vitro and vivo literature regarding the immunomodulatory effects of 
psychiatric medications. 
  The current findings are also in line with the macrophage-T lymphocyte theory 
(Smith and Maes, 1995), suggesting the implication of IL-1, IL-2, TNF-α and IFN-γ 
produced by chronically activated macrophages and T-lymphocytes. Our results are 
also in agreement with the microglial hypothesis (Monji et al., 2009), predicting 
activation of the Central Nervous System (CNS) microglia and subsequent release of 
pro-inflammatory cytokines (TNF-a, IFN-γ), thus causing abnormal neurogenesis and 
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neuronal degradation. A recent multisite study in UHR cohorts (Cannon et al., 2015) 
favored a predictive role of pro-inflammatory cytokines  for conversion to psychosis. 
On the contrary, a recent meta-analysis (Upthegrove et al., 2014) on drug naïve FEP 
population showed no significant effect for IFN-γ and IL-2. Again any interpretation 
should be cautious due to the lack of HC group in the present study. 
In addition, our FEP sample presented with increased levels of IL-10 compared with 
the UHR group, thus offering indirectly (due to the lack of HC group) grounds to the 
hypothesis of a simultaneous mobilization of both the pro- and anti-inflammatory 
cytokine networks (Drexhage et al., 2011). Interestingly, IL-10 was associated with 
TNF-a within each group, but with an inverse mode (positively within FEP vs 
negatively in UHR). If someone takes in mind the seemingly oppositional findings of 
an association of polymorphic haplotypes IL-10 gene with schizophrenia (Bocchio et 
al., 2002) on the one hand, and the IL-10’s protective role against inflammation 
mediated degeneration of dopaminergic neurons in Substantia Nigra (Arimoto et al., 
2007) on the other, then an ambiguous role for IL-10 arises. The field becomes more 
perplex with the publication of preliminary data from studies in the UHR suggesting 
a role for IL-6 (Stojanovic et al., 2014), IL-7 and IL-8 (Perkins et al., 2015). These 
cytokines can trigger a shift towards activation of a T helper type 2 immune response 
and autoimmunity (Zhang et al., 2002; Dooms, 2013), similarly to IL-10. In an 
attempt to incorporate the multifaceted findings of the current study along with the 
hitherto evidence and preliminary findings (to be published) from our group on FEP 
subjects, showing significantly higher IL-4 levels compared with HC, the authors tend 
to favor the activation of both the inner and adaptive arms of immunity as well as 
the simultaneous mobilization/secretion of the pro- and anti-inflammatory series of 
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cytokines, as a possible aetiopathogenetic hypothesis of psychosis from the immune 
dysregulation point of view. 
 Future research needs to shed more light on the exact sequence of the immune 
cascades as well as on the arbitrary aetiopathogenetic or neuroprotective role of IL-
10.   
4.2 HPA axis function 
With regards to the HPA axis function, the findings were more vague, as only a trend 
for increase of both the mean AUCg cortisol and the mean AUCi cortisol change in 
the UHR was shown, compared with the FEP group. These results could imply a 
subtle hyper secretion of cortisol, along with a tendency for higher cortisol 
fluctuation/decline in the UHR group, in relation to the FEP group. According to 2 
latest reviews, which suggest a tendency for up regulation of the HPA axis function in 
FEP state (Karanikas et al., 2014) and even prior to the emergence of full blown 
psychosis (Karanikas and Garyfallos, 2015), compared with the Healthy Control state, 
we could anticipate that both of the groups in our study might have their HPA axes 
up regulated. Maybe this is the reason why there was no clear difference between 
the 2 groups regarding the cortisol secretion. 
 Moreover, the results from the DST did not reveal any difference either in the pre-
post/Dex cort levels or in the suppressors’ rates between the compared groups. 
Interestingly, when the sensitivity of the non-suppression detection was increased 
by lowering the cutoff of post/Dex cort to 2 μg/dl, the non-suppressors FEP patients 
were doubled compared with the commonly used cutoff of 5μg/dl, yet not still 
differing significantly from the UHR counterparts. Surprisingly the detection of non-
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suppressors only within the FEP group was not combined with increased secretion of 
cortisol in this particular group vs the UHR counterparts. Again the lack of HC group 
posits limits to further exploration of possible neuroendocrine alterations.  
To further blur the landscape, the hitherto data regarding the application of DST in 
FEP cohorts are minimal and contradictory. Cesková et al.(2006),  in a study without 
HC, demonstrated higher rates of DST (1 mg Dex, cutoff:5μg/dl) non suppression in 
FEP schizophrenic patients during the acute phase of the illness whereas a recent 
study (Phassouliotis et al., 2013) involving a variation of DST (0.25 mg Dex, 
cutoff:5μg/dl) on FEP patients-diagnosed with both affective and non-affective 
disorders of the psychotic spectrum- and HC, reported no group differences in 
cortisol decline as well as higher rate of hyper suppressors FEP patients in relation to 
HC. To the best of our knowledge, no DST studies have been conducted on UHR 
populations till now. Thus, more studies with larger cohorts, including an additional 
HC group, are needed to delineate the severity and sequence of neuroendocrine 
alterations both at prodrome and FEP.  
In contrast, the 2 compared groups in our study, exhibited clearer differences in their 
immune profile when being compared in between them. This preponderance of the 
evidence for immunological alteration, as opposed to the more subtle endocrine 
differentiation in the FEP state vs the UHR state, may potentiate the principally 
inflammatory aetiopathogenetic hypothesis in psychosis. Thus, the presumption 
(Altamura et al., 1999; Mondelli and Howes, 2014) that inflammatory cytokinaemia 
precedes and triggers the HPA axis in the context of the psychotic pathophysiological 
process, could be justified. Conversely, it could be assumed that a deficient HPA axis, 
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with regard to the cortisol secretion and/or fluctuation/reactivity, may not efficiently 
offer anti-inflammatory protection, thus rendering the organism vulnerable to 
disinhibited inflammatory immune reactions (Baumeister et al., 2014). The finding 
that the HPA axis function, in the FEP group of our study, showed a trend for less 
reactivity, compared with the UHR, may explain the significantly increased circulating 
pro-inflammatory cytokines in this group as opposed to the prodromal counterparts. 
4.3 Strengths and Limitations 
Collectively, this study represents a first attempt to compare the immune state of 
FEP with the prodrome. Additionally, the comprehensive investigation of the HPA 
axis function, through the estimation of cortisol’s secretion, fluctuation and 
suppressive capacity as well as the evaluation of the psychopathology, all add to the 
strengths of the study. A lack of a HC group, the small cohorts and the restriction of 
the cohorts to only male gender could be considered as drawbacks. Also the lack of 
measurement of both the serum Dex levels and the post/Dex cort in the afternoon 
need to be included in the limitations. Lastly, the cross sectional design of the study 
eliminate the capacity for exploration of causal relationships within the psycho-
immuno-endocrine context.   
In conclusion, the results strengthen the evidence for increased inflammation 
playing a role in the aetiopathogenesis of psychosis. The exact sequence among the 
immune, endocrine and psychopathology mechanisms needs to be further clarified. 
Longitudinal studies proximal to the psychotic conversion are likely to be further 
enlightening.  
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Figure 1. Cytokine mean scores in the two research groups (logarithmically transformed 
values, bars represent 95% confidence intervals) UHR: Ultra High Risk for Psychosis, FEP:First 
Episode Psychosis. 
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TABLE 1 
     Group demographics, clinical data, cytokine levels and cortisol 
measurements 
    ACRP (N=12) FEP (N=25)       
Demographics Mean (SD) Mean (SD) 
Mann 
Whitney U Z p 
Age  
24.5 (3.1) 25.48 (5.4) 
148.5 
0.04
9 0.961 
Education  
13.16 (2.1) 12.44 (1.8) 
126 
0.86
4 0.388 
ΒΜΙ 
24.15 (1.9) 24.8 (4.2) 
141 
0.29
2 0.77 
Clinical 
Assesment Mean (SD) Mean (SD) 
Mann 
Whitney U Z p 
PANSS PF 
4.92 (9.06) 18.64 (4.7) 
43.5 
3,48
8 
<0.00
1 
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PANSS NF 5.33 (9.78) 18.4 (4.2) 52 3.21 0.001 
PANSS GP 
8.92 (16.27) 35.36 (5.37) 
41.5 
3,55
1 
<0.00
1 
PANSS TOTAL 
19.17 (34.75) 72.8 (11.2) 
50 
3,26
9 0.001 
Cytokines 
Median 
(25th,75th) 
Median 
(25th,75th) 
Mann 
Whitney U Z p 
IL-1b 64 (40,67) 51 (39,117) 
128 
0.71
4 0.491 
IL-2 95 (94,97) 99 (96,121) 
79 
2,30
6 0.021 
IL-4 71(70,71) 71 (69,76) 
148 
0.06
5 0.948 
IL-5 0.4 (0.4,3.8) 11.5 (0.4, 53) 
103 
1,66
2 0.097 
IL-8 331 (0.2,1028) 218 (35,694) 
141 
0.29
4 0.769 
IL-10 6 (1,7) 19 (4,55) 
76 
2,40
7 0.016 
IL-12p70 11 (10,12) 14 (11,23) 
79 
2,30
7 0.021 
IFN-γ 20 (17,27) 39 (23,122) 
68 
2,66
4 0.008 
TNF-a 0.8(0.8,0.8) 9(0.8,69.4) 
67.5 
2,84
6 0.004 
TNF-b 0.6(0.6,0.6) 0.6 (0.6,50) 
129 
0.87
1 0.384 
Cortisol Mean (SD) Mean (SD) Mann 
Whitney U Z p 
AUCg 206.4(72.85) 170.44(61.91) 97.5 1.70 0.088 
AUCi 
80.63(56.45) 42.37(58.88) 93 
1,84
9 0.064 
pre-
post/Dexcort 12.80(3.49) 10.45(4.44) 109 1.33 0.183 
      
      UHR: Ultra High Risk for Psychosis, FEP: First Episode 
Psychosis   
        Age, Education in years; BMI: Body Mass Index  
        PANSS: Positive and Negative Syndrome Scale; [PF: Positive Factor, NF: Negative 
Factor,  
 GP: General Psychopathology, TOTAL: Total score], IL: Interleukin, IFN: Interferon, TNF: 
Tumor Necrosis Factor 
AUCg:Area Under Curve ground, AUCi: Area Under Curve 
increase,  
   pre-post/Dex cort: cortisol levels prior Dex minus cortisol post Dex, Dex: 
Dexamethasone   
 Cytokine levels presented as median, 25th,75th percentile in pg/ml 
   AUCg-AUGi: absolute values in μg/dl/min, pre-post Dex cort in μg/dl  
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 p: Between -group differences  with the Mann-Whitney test, p set at 0.05 
  
       
 
 
 
  
